316 related articles for article (PubMed ID: 24840269)
1. Overcoming toxicity and side-effects of lipid-lowering therapies.
Wilkinson MJ; Laffin LJ; Davidson MH
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):439-52. PubMed ID: 24840269
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. Statin safety: an overview and assessment of the data--2005.
Bays H
Am J Cardiol; 2006 Apr; 97(8A):6C-26C. PubMed ID: 16581330
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
5. How well tolerated are lipid-lowering drugs?
Tomlinson B; Chan P; Lan W
Drugs Aging; 2001; 18(9):665-83. PubMed ID: 11599634
[TBL] [Abstract][Full Text] [Related]
6. Are statins really wonder drugs?
Grover HS; Luthra S; Maroo S
J Formos Med Assoc; 2014 Dec; 113(12):892-8. PubMed ID: 24231094
[TBL] [Abstract][Full Text] [Related]
7. Addressing statin adverse effects in the clinic: the 5 Ms.
Katz DH; Intwala SS; Stone NJ
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):533-42. PubMed ID: 24770611
[TBL] [Abstract][Full Text] [Related]
8. Treatment Options for Statin-Associated Muscle Symptoms.
Laufs U; Scharnagl H; Halle M; Windler E; Endres M; März W
Dtsch Arztebl Int; 2015 Oct; 112(44):748-55. PubMed ID: 26575138
[TBL] [Abstract][Full Text] [Related]
9. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
[TBL] [Abstract][Full Text] [Related]
10. Statin intolerance: now a solved problem.
Sikka P; Kapoor S; Bindra VK; Sharma M; Vishwakarma P; Saxena KK
J Postgrad Med; 2011; 57(4):321-8. PubMed ID: 22120862
[TBL] [Abstract][Full Text] [Related]
11. [Statin intolerance].
Tonstad S
Tidsskr Nor Laegeforen; 2017 Jan; 137(1):36-38. PubMed ID: 28073228
[TBL] [Abstract][Full Text] [Related]
12. An overview of statin-induced myopathy and perspectives for the future.
Nikolic D; Banach M; Chianetta R; Luzzu LM; Pantea Stoian A; Diaconu CC; Citarrella R; Montalto G; Rizzo M
Expert Opin Drug Saf; 2020 May; 19(5):601-615. PubMed ID: 32233708
[No Abstract] [Full Text] [Related]
13. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
14. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
[TBL] [Abstract][Full Text] [Related]
15. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
16. [Statin myopathy--rarity or reality?].
Pella D
Vnitr Lek; 2010 Sep; 56(9 Suppl):972-6. PubMed ID: 21137170
[TBL] [Abstract][Full Text] [Related]
17. [Impact of lipid lowering therapy on liver function].
Paragh G; Fülöp P
Orv Hetil; 2009 Jun; 150(26):1205-12. PubMed ID: 19546077
[TBL] [Abstract][Full Text] [Related]
18. Managing statin-induced muscle toxicity in a lipid clinic.
Blaier O; Lishner M; Elis A
J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
[TBL] [Abstract][Full Text] [Related]
19. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?
Cornier MA; Eckel RH
Curr Atheroscler Rep; 2015; 17(2):475. PubMed ID: 25432858
[TBL] [Abstract][Full Text] [Related]
20. Managing the underestimated risk of statin-associated myopathy.
Rallidis LS; Fountoulaki K; Anastasiou-Nana M
Int J Cardiol; 2012 Sep; 159(3):169-76. PubMed ID: 21813193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
